Komori
Terumo (4543) · FactAdvanced

Changes in Debt Composition Due to Bond Issuance and Repayment of Long-Term Borrowings

First written in FY2025-H1. 5 of 6 entries say "Advanced", first in FY2025. Latest entry: 2026-08-07.

6entries
3years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2025-H1AdvancedFY2025 – 2026-08-072024: 120242025: 220252026: 32026
Same theme, other companies
Financing Through Long-Term Borrowings and Bonds and the Shift in Debt StructureA theme 88 companies write about · 12 as a headwind · 37 as a tailwind

15 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 88 companies compared. The sentences above are computed from all 88.
Full recordFilings, disclosures and news, newest first
  1. 2026-08-07AdvancedEarnings

    「The main factors were ¥98.8 billion in proceeds from long-term borrowings and ¥79.3 billion in proceeds from the issuance of bonds.」

    Financing through long-term borrowings and bond issuance appeared in first-quarter financing activities, indicating continued changes in the liability structure.
  2. FY2026AdvancedAnnual report

    「Total liabilities at the end of the fiscal year were ¥727.7 billion, an increase of ¥267.9 billion from the end of the previous fiscal year. This was mainly due to a ¥205 billion increase in bonds and borrowings resulting from borrowings to fund the acquisition of OrganOx, Ltd. and other factors.」

    Borrowings to fund the acquisition of OrganOx increased bonds and borrowings by ¥205 billion, significantly changing the debt structure. After the filing, the Company also refinanced through US dollar-denominated bonds and long-term borrowings.
  3. 2026-05-15AdvancedEarnings

    「This was due to a ¥205.0 billion increase in bonds and borrowings resulting from borrowings made for the acquisition of OrganOx and other factors.」

    The Company disclosed an increase in bonds and borrowings in its full-year financial position as a result of borrowings associated with the acquisition of OrganOx.
  4. FY2026-H1AdvancedAnnual report

    「Based on a resolution of the Board of Directors meeting held on 17 October 2025, the Company entered into loan agreements with MUFG Bank, Ltd. and Mizuho Bank, Ltd. dated 24 October 2025, and borrowed the funds on 29 October 2025. 1. Purpose of borrowing: to fund the acquisition of OrganOx 3. Amount borrowed: ¥240 billion」

    After the end of FY2026-H1, the Company drew down ¥240 billion in borrowings to fund the acquisition of OrganOx. In addition to the existing mix of bonds and long-term borrowings, the acquisition financing has resulted in a change in the debt structure.
  5. FY2025AdvancedAnnual report

    「Proceeds of ¥30 billion from long-term borrowings, proceeds of ¥69.8 billion from bond issuance, proceeds of ¥25.4 billion from settlement of derivatives, and payments of ¥160.3 billion for repayment of long-term borrowings」

    A review of the debt structure through bond issuance and repayment of long-term borrowings was also confirmed for the full fiscal year. The balance of bonds increased from ¥19.978 billion to ¥89.855 billion, while long-term borrowings decreased as a result of repayments.
  6. FY2025-H1First statedAnnual report

    「The main factors were proceeds of ¥30 billion from long-term borrowings, proceeds of ¥69.8 billion from bond issuance, proceeds of ¥25.4 billion from settlement of derivatives, payments of ¥160.3 billion for repayment of long-term borrowings, and dividend payments of ¥16.3 billion.」

    During the interim consolidated accounting period, the Company issued a total of ¥70 billion in unsecured bonds while repaying ¥160.3 billion in long-term borrowings. Bonds and borrowings decreased by ¥57 billion, resulting in a change in the debt structure.
Moved together

"Expanding market share in global markets and enhancing brand value" moved the same way as this thread, in the same document, in 5 of its 6 moves.

554444★123456
  1. ★This thread
  2. 1Expanding market share in global markets and enhancing brand value5×
  3. 2Managing Business Performance Using Adjusted Operating Profit5×
  4. 3Growth in the Blood Systems business centered on apheresis, cell processing and emerging markets4×
  5. 4Becoming a Company with a Strong Global Presence and Achieving Sustainable, Profitable, High-Quality Growth4×
  6. 5Global sales expansion of cardiovascular products such as Ultimaster4×
  7. 6Strengthening Cost Competitiveness Through Products Tailored to Regional Needs and a Global Production Network4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Terumo yet. It last moved in the Earnings of 2026-08-07: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Changes in Debt Composition Due to Bond Issuance and Repayment of Long-Term Borrowings | TERUMO CORPORATION (4543) | Komori